Endologix Announces that Lucas Buchanan Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)-- Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors.

Lucas Buchanan is currently the Chief Financial Officer and Chief Operating Officer at Silk Road Medical, Inc. He is widely recognized for his contributions to Silk Road Medical as the company introduced a new therapy for the treatment of carotid artery stenosis and changed the paradigm for patients with cerebrovascular disease. Mr. Buchanan played a pivotal role in financing the company and scaling its operations, including leading Silk Road’s initial public offering in 2019, and his role has continued to expand. Prior to Silk Road Medical, Mr. Buchanan’s background includes investing, business development, and operating roles at The Vertical Group, Impax Laboratories, Medtronic, and Ernst & Young. He holds an MBA in Health Care Management from The Wharton School at the University of Pennsylvania and a BA in Economics from Duke University.

“We are thrilled to welcome Lucas to our Board of Directors,” said Matt Thompson, MD, President, and CEO of Endologix. “With his deep industry knowledge of the medical device industry, private and public company governance and fundraising, and his exceptional leadership skills, we are confident that Lucas will play a key oversight role as we continue to pursue our goal of transforming Endologix into a high growth medical technology company. Lucas’ experience as a leader of a company that is pioneering a new therapy will be invaluable as we continue the launch of the DETOUR System, our disruptive therapy for percutaneous transmural arterial bypass (PTAB) and continue to broaden our product portfolio.”

Mr. Buchanan expressed his excitement at joining the Endologix Board by stating, “I am looking forward to working with the Board of Directors and leadership team to drive Endologix’s strategic priorities. Having spent nearly 25 years in the medical devices industry, I have had the privilege of witnessing the transformative impact that innovative therapies can have and feel that Endologix’s disruptive therapeutic portfolio can deliver improved outcomes for patients.”

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX^®2 Endovascular AAA System, ALTO^® Abdominal Stent Graft System, and the DETOUR^TM System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230824037169/en/